1. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
- Author
-
Chen, Qiushi, Jain, Nitin, Ayer, Turgay, Wierda, William G, Flowers, Christopher R, O'Brien, Susan M, Keating, Michael J, Kantarjian, Hagop M, and Chhatwal, Jagpreet
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Clinical Trials and Supportive Activities ,Dental/Oral and Craniofacial Disease ,Cost Effectiveness Research ,Hematology ,Comparative Effectiveness Research ,Clinical Research ,Cancer ,Lymphoma ,Good Health and Well Being ,Cost of Illness ,Cost-Benefit Analysis ,Costs and Cost Analysis ,Humans ,Leukemia ,Lymphocytic ,Chronic ,B-Cell ,Models ,Theoretical ,Quality of Life ,United States ,Clinical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
Purpose Oral targeted therapies represent a significant advance for the treatment of patients with chronic lymphocytic leukemia (CLL); however, their high cost has raised concerns about affordability and the economic impact on society. Our objective was to project the future prevalence and cost burden of CLL in the era of oral targeted therapies in the United States. Methods We developed a simulation model that evaluated the evolving management of CLL from 2011 to 2025: chemoimmunotherapy (CIT) as the standard of care before 2014, oral targeted therapies for patients with del(17p) and relapsed CLL from 2014, and for first-line treatment from 2016 onward. A comparator scenario also was simulated where CIT remained the standard of care throughout. Disease progression and survival parameters for each therapy were based on published clinical trials. Results The number of people living with CLL in the United States is projected to increase from 128,000 in 2011 to 199,000 by 2025 (55% increase) due to improved survival; meanwhile, the annual cost of CLL management will increase from $0.74 billion to $5.13 billion (590% increase). The per-patient lifetime cost of CLL treatment will increase from $147,000 to $604,000 (310% increase) as oral targeted therapies become the first-line treatment. For patients enrolled in Medicare, the corresponding total out-of-pocket cost will increase from $9,200 to $57,000 (520% increase). Compared with the CIT scenario, oral targeted therapies resulted in an incremental cost-effectiveness ratio of $189,000 per quality-adjusted life-year. Conclusion The increased benefit and cost of oral targeted therapies is projected to enhance CLL survivorship but can impose a substantial financial burden on both patients and payers. More sustainable pricing strategies for targeted therapies are needed to avoid financial toxicity to patients.
- Published
- 2017